Over the last 7 days, the United States market has risen by 2.2% and is up 31% over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and potential for substantial revenue expansion.
Top 10 High Growth Tech Companies In The United States
We’re going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Digi Power X Inc. is an energy infrastructure company that focuses on developing data centers to enhance energy asset expansion in the United States, with a market cap of $467.24 million.
Operations: Digi Power X generates revenue primarily through colocation services, cryptocurrency mining, and the sale of energy and electricity, with colocation services contributing $17.47 million. The company also earns $13.20 million from energy and electricity sales.
Digi Power X’s strategic pivot from Bitcoin mining to AI infrastructure is timely, tapping into the high-demand Tier 3 data center market with its ARMS platform designed for rapid deployment and scalability. This move is underscored by a recent $19.6 million GPU rental agreement with SubQ AI, leveraging its NeoCloudz platform to offer cutting-edge NVIDIA Blackwell GPUs. Despite a challenging financial year with revenues dipping to $34.19 million and widening net losses of $28.36 million, these initiatives signal a robust entry into AI services, expected to generate significant revenue by Q3 2026 as it scales up operations in Alabama and New York sites.
DGXX Revenue and Expenses Breakdown as at May 2026
Simply Wall St Growth Rating: ★★★★★☆
Overview: Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor cell therapy for light chain Amyloidosis and immune-mediated diseases, with a market cap of $516.87 million.
Operations: Immix Biopharma, Inc. develops innovative therapies targeting light chain Amyloidosis and immune-mediated diseases in the U.S. and Australia. As a clinical-stage company, it focuses on advancing its chimeric antigen receptor cell therapy through various stages of development without current revenue streams from product sales.
Immix Biopharma’s recent strategic advancements, including the completion of NEXICART-2 enrollment and its expected Q3 results, underscore its potential in addressing AL Amyloidosis with its innovative CAR-T therapy, NXC-201. Despite a challenging financial backdrop with a widened net loss of $10.09 million in Q1 2026 from $4.54 million the previous year, these developments could pivot towards significant commercial opportunities. The company’s focus on this high-stakes biotech segment aligns with an expanding market projected to reach $6 billion by 2025, positioning it well within a niche yet rapidly growing sector of medical technology.
IMMX Earnings and Revenue Growth as at May 2026
Simply Wall St Growth Rating: ★★★★★☆
Overview: Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for inflammatory-related diseases, with a market cap of $932.26 million.
Operations: Annexon, Inc. specializes in the development of treatments for inflammatory-related diseases as a clinical-stage biopharmaceutical entity. The company’s operations are currently not generating revenue, reflecting its focus on research and development activities.
Amidst a challenging landscape, Annexon has shown resilience with a notable reduction in its quarterly net loss to $44.14 million from $54.36 million year-over-year, reflecting tighter control over operational expenses and strategic R&D investments. The company’s recent presentations at high-profile healthcare conferences highlight its commitment to advancing treatments for neurodegenerative diseases, positioning it as an emerging player in the biotech sector with potential for significant impact. With an ambitious pipeline focused on neuroprotective therapies and a clear strategy aimed at addressing unmet medical needs, Annexon’s ongoing research could catalyze future growth as it moves closer to profitability forecasted within three years.
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
Streamline your investment strategy with Simply Wall St’s app for free and benefit from extensive research on stocks across all corners of the world.
Contemplating Other Strategies?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DGXXIMMX and ANNX.
Leave a comment